TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Price, Forecast & Analysis
NYSE:TAK • US8740602052
TAK Key Statistics, Chart & Performance
The current stock price of TAK is 18.65 USD. In the past month the price increased by 12.28%. In the past year, price increased by 29.42%.
TAK Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TAK. When comparing the yearly performance of all stocks, TAK is one of the better performing stocks in the market, outperforming 85.97% of all stocks.
TAK Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TAK. While TAK has a great profitability rating, there are quite some concerns on its financial health.
TAK Financial Highlights
Over the last trailing twelve months TAK reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS decreased by -45.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.53% | ||
| ROA | 0.73% | ||
| ROE | 1.48% | ||
| Debt/Equity | 0.56 |
TAK Forecast & Estimates
19 analysts have analysed TAK and the average price target is 17.61 USD. This implies a price decrease of -5.57% is expected in the next year compared to the current price of 18.65.
For the next year, analysts expect an EPS growth of 74.27% and a revenue growth -1.51% for TAK
TAK Ownership
TAK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.05 | 1.001T | ||
| JNJ | JOHNSON & JOHNSON | 21.14 | 592.302B | ||
| MRK | MERCK & CO. INC. | 22.9 | 307.324B | ||
| PFE | PFIZER INC | 9.04 | 153.855B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.12 | 124.69B | ||
| ZTS | ZOETIS INC | 18.73 | 55.434B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.247B | ||
| VTRS | VIATRIS INC | 6.35 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.23 | 12.297B | ||
| AXSM | AXSOME THERAPEUTICS INC | 207.52 | 8.81B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TAK
Company Profile
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
Company Info
TAKEDA PHARMACEUTIC-SP ADR
4F, 2-1-1, Nihombashihon-cho
Chuo-Ku TOKYO-TO 103-8668 JP
CEO: Christophe Weber
Employees: 49281
Phone: 81332782111
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What does TAK do?
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
What is the current price of TAK stock?
The current stock price of TAK is 18.65 USD. The price decreased by -0.8% in the last trading session.
Does TAK stock pay dividends?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a dividend yield of 3.44%. The yearly dividend amount is currently 0.62.
How is the ChartMill rating for TAKEDA PHARMACEUTIC-SP ADR?
TAK has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Would investing in TAKEDA PHARMACEUTIC-SP ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TAK.
What is the market capitalization of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a market capitalization of 58.92B USD. This makes TAK a Large Cap stock.
What is the Short Interest ratio of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
The outstanding short interest for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 0.25% of its float.